DelveInsight's 'Systemic Lupus Erythematosus Pipeline Insight 2024' report provides comprehensive global coverage of pipeline ...

SLE: Systemic lupus erythematosus. Symptoms of systemic lupus erythematosus (SLE) must be brought under control to avert immediate consequences and afford the patient a better quality of life.

Phase 3 trial of Biogen and UCB's dapirolizumab pegol shows significant improvement in lupus disease activity. Read more here ...

Long-term treatment with anifrolumab significantly reduced the rate of organ damage compared with SOC among patients with SLE ...

After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...

A novel study published in the journal PLOS ONE highlighted the effects of hydroxychloroquine on cardiovascular risk factors ...

USA: A recent study has highlighted significant barriers to cervical cancer screening among women with systemic lupus ...

Alumis' lead clinical candidate, ESK-001, is a potent, highly selective allosteric tyrosine kinase 2 (TYK2) inhibitor that reduces signaling through several cytokine receptors including receptors for ...

The American College of Rheumatology (ACR) 2024 Convergence has just concluded, showcasing significant advancements and ...

Natural treatments for lupus are typically used as complementary therapies alongside conventional treatments. Learn more ...

Fate Therapeutics, Inc. FATE presented encouraging initial clinical and translational data from the first patient treated in ...